A third Novartis biopharmaceutical has received breakthrough designation status from the FDA allowing ‘fast-track’ development and review without compromising safety, the company says.
Mammalian cell culture know-how and location won Rentschler Biotechnologie its new anticancer MAb manufacturing deal according Austrian BioPharma Apeiron Biologics.
The global bioseparation systems market is projected to almost double in size from $3.25B in 2012 to $6B in 2018, at a compound annual growth rate of about 11%, according to a recent report on the market.
Quality concerns and high shipping costs mean BioPharmas currently prefer Western CMOs, but improving standards and market opportunities may soon make Chinese contractors more attractive, experts say.
Keeping up with the latest technology news is a must for biomanufacturers according to an MIT Professor who told BioPharma-Reporter.com new advances in microtechnologies could help address process development challenges.
GE Healthcare and iBio are in talks about future projects after confirming they are working on a plant-based vaccine manufacturing site for Brazilian drugmaker Fiocruz/Bio-Manguinhosin.
Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
GE Healthcare has started designing a vaccine manufacturing facility for an unnamed drug company, just days after expanding its collaboration with plant-cell production technology firm iBio.
Prokarium – a biotech company that was formerly part of UK CMO Cobra Biologics spin-out - has bought an oral vaccine technology from Emergent BioSolutions.
March has already been a busy month for the biomanufacturing technology sector and here is in-Pharmatechnologist.com’s round-up of some of the developments so far.
GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
Large volume production is a must for the cell therapy sector according to ATMI, which claims the latest addition to its single-use bioreactor range can help manufacturers overcome the GMP hurdles that hinder commercial scale-up.
Processing technology maker Pall has opened a new centre of excellence in Singapore in a bid to capture a share of the country’s growing biomanufacturing sector.
CellCura has inked an agreement with IDT Biologika for the testing and adaptation of its protein-free (PF) media for the production of cell lines for vaccine manufacturing.
DSM Biologicals has launched a new production method designed to streamline downstream processing during biopharmaceutical manufacturing that, it claims, makes making mAB-based drugs more cost effective.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
Sartorius Stedim Biotech (SSB) has teamed up with packaging firm Sudpack Medica AG in a deal focused on making plastic films for biopharmaceutical industry applications.
Florida-based contract manufacturing organisation (CMO), Goodwin Biotechnology (GBI), has entered into an agreement with protein and monoclonal antibody drug developer, Rafagen, to provide cell line engineering and biological contract manufacturing services.
Californian Bioreactor manufacturer, PBS Biotech, has launched its new PBS 3 single-use bioreactor system for the development of biological therapeutics, vaccines and biosimilars.
Sartorius Stedim Biotech (SSB) has launched a new small-scale bioreactor citing growing biopharmaceutical company demand for scale-up technologies as the key driver for its development.
Almac Pharma Services has expanded its cold storage capacity for biopharmaceuticals, continuing the contract manufacturing organisation’s (CMO) busy expansion programme.
in-PharmaTechnologist presents its latest round up of movements in the pharma sector, including appointments at Euthymics, CytomX, NPS Pharmaceuticals and InQ Biosciences.
Crucell and Eden Biodesign have entered into an agreement that sees Eden become a provider of services of contract manufacturing services for Crucell's PER.C6 cell-line technology.
ATMI has acquired Artelis, a Belgian biotech firm, in an effort to “get closer to customers” by widening its disposable technology portfolio to the life sciences research and manufacturing sector.
SGS Life Sciences will roll out new biologics testing capabilities across its network in bid to be the world’s number one contract biopharmaceuticals testing laboratory by 2014.